tbuckley/cabot-search huggingface dataset:
SP0139 A Pseudomalignant Autoimmune Disease with many Different Faces
Authors: P.L. Klarenbeek
Journal: Annals of the Rheumatic Diseases (2015)

A number of puzzling autoimmune syndromes has recently been clustered around the same immunological feature: infiltration of tissue by IgG4 producing plasma cells. Collectively these diseases are called the IgG4 related diseases (IgG4-RD). Despite recent advances in understanding these diseases, making the diagnosis is challenging as invasive diagnostic procedures and specific tests are required. Nevertheless, diagnosing IgG4-RD is rewarding as these diseases are often mistaken for malignancy. In this presentation we will discuss several cases to demonstrate the challenges in the diagnostic process. <h3>Disclosure of Interest</h3> None declared
PTU-323 Cost effective resourcing of a colitis chromoendoscopy service from implementing new bsg barrett’s surveillance guidelines
Authors: P Oka, P Kant
Journal: Gut (2015)

<h3>Introduction</h3> Pan-colonic chromendoscopy (CE) is the gold standard for colitis surveillance. High quality procedures can reduce histology costs but require greater expertise but also additional time, estimated at 1 endoscopy slot per procedure. These, together with a competing rise in endoscopy demand have hindered the extra resource allocation for its widespread implementation. New BSG Barrett's oesophagus (BO) surveillance guidelines have changed from previously biennial to lengthened surveillance intervals depending on an individual's maximal BO length. The aim of this study was to model the reduction in endoscopic demand in our surveillance cohort after adoption of the new 2014 BSG guidelines and to determine whether sufficient capacity can be created to fully resource a dedicated CE service. <h3>Method</h3> A retrospective analysis of all BO patients at York Hospital in 5 years between 2009 and 2013 was performed. The endoscopy and histology costs based on complete adherence to old BO guidelines were calculated on an annualised basis. Patients were split into 3 groups: those who did not have IM and could be discharged; those with short (&lt;3 cm) BO were to be changed to 5 yearly surveillance; whilst those with long (≥3 cms) BO were changed to 3 yearly surveillance. The volume of endoscopy capacity created and the histology cost savings were calculated. Next, we looked at the number of conventional colitis surveillance colonoscopies performed per year over the same period of time with associated histology costs of serial biopsies. <h3>Results</h3> Between 2009 and 2013, 453 BO surveillance patients, according to old BSG guidelines would require a mean of 227 OGDs per annum (p.a.). Based on current NHS tariffs and combined with associated histology costs, this would equate to £123,443 p.a. Seven (4.4%) patients had no evidence of IM and according to new BSG guidelines could potentially be discharged; 112 (24.7%) had short BO and 321 (70.9%) had long BO. Maximising their surveillance intervals would result in 128 surveillance OGDs and £69,940 in combined costs, thus freeing up a mean of 98 endoscopy slots p.a. with an overall annual cost saving of £53,503. Over the same period a mean of 92 surveillance colonoscopies were carried out for colitis with estimated histology costs of £18,400 p.a. Adopting Chromoendoscopy with targeted biopsies would reduce histology costs to £6,900, saving £11,500 per year. <h3>Conclusion</h3> The provision of extra endoscopy capacity for CE can almost entirely be met by adoption of the new BSG BO surveillance guidelines. Furthermore, the combined approach yields an overall net histology cost saving of around £14,000 p.a. These cost analyses should support individual NHS Trust's business cases for the widespread implementation of CE. <h3>Disclosure of interest</h3> None Declared.
Experimental Cancer of the Lung
Authors: L M SHABAD
Journal: JNCI Journal of the National Cancer Institute (1962)

Journal Article Experimental Cancer of the Lung Get access L. M. Shabad L. M. Shabad Institute of Experimental and Clinical Oncology, Academy of Medical Sciences of the U.S.S.R., Moscow, U.S.S.R. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 28, Issue 6, June 1962, Pages 1305–1332, https://doi.org/10.1093/jnci/28.6.1305 Published: 01 June 1962 Article history Received: 21 November 1961 Revision received: 16 March 1962 Published: 01 June 1962
PHYSICIAN PARTICIPATION IN OLYMPIC GAME PLANNING
Authors: H A RASKIN
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effects of diagnosis and treatment history on relapse of psychiatric patients
Authors: A D Pokorny, H B Kaplan, R J Lorimor
Journal: American Journal of Psychiatry (1983)

Of 400 patients followed up for 1 year after release from the hospital, 34% were readmitted during that year. For schizophrenic patients the readmission rate was 49%, and for nonschizophrenic patients it was 21%. Rate of rehospitalization was positively related to number of prior hospitalizations, cumulative months of prior hospitalization, and duration of illness, but the relationship varied between the schizophrenic and nonschizophrenic groups. In contrast to the findings of Linn and associates, in this study prior hospitalization of nonschizophrenic patients markedly increased the likelihood of rehospitalization.
Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib
Authors: Sung-Eun Lee, Soo Young Choi, Jae-Yong Kwak, Hawk Kim, Jeong-A Kim, Young Rok Do, Hyeoung Joon Kim, Joon Seong Park, Joo Seop Chung, Ho-Jin Shin, Sung-Hyun Kim, Dae-Young Kim, Udomsak Bunworasate, Chul Won Choi, Narcisa Sonia Cornejo Comia, Dae Young Zang, Sukjoong Oh, Saengsuree Jootar, Ary Harryanto Reksodiputro, Won Sik Lee, Yeung-Chul Mun, Jee Hyun Kong, Priscilla B. Caguioa, Jinny Park, Chul Won Jung, Dong-Wook Kim
Journal: Blood (2015)
OP0188 Impact of Hydroxychloroquine Treatment on Pregnancy Outcome in Patients with Antiphospholipid Antibodies
Authors: S. Sciascia, B.J. Hunt, E. Talavera, G. Lliso, D. Roccatello, M. Khamashta, M.J. Cuadrado
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Current treatment does not prevent all maternal, foetal and neonatal complications of antiphospholipid syndorme (APS), with an overall frequency of failure despite modern treatment ranges from 20 to 30% <h3>Objectives</h3> To assess the pregnancy outcome in women with antiphospholipid antibody (aPL) treated with hydroxychloroquine (HCQ) during pregnancy <h3>Methods</h3> This observational, retrospective, single centre clinical study included 170 pregnancies in 96 women with persistent aPL. Sixty-five consecutive pregnancies occurred in 31 women treated with HCQ for at least 6 months prior to pregnancy. HCQ was continued throughout gestation (group A). One-hundred nineteen consecutive pregnancies occurred in 65 women with aPL who had not been treated with HCQ prior to conception acted as controls (group B). <h3>Results</h3> HCQ treatment was associated with a significantly higher rate of live births (66.7% in group A vs. 57.1% in group B, p=0.05) and a lower rate of pregnancy morbidity (47.1% in group A vs. 63.0% in group B, p=0.004). We observed a higher prevalence of spontaneous vaginal labour in HCQ-treated women compared to group B (37.3% vs. 14.3%, p=0.01). Pregnancy duration was longer in group A than B (27.6 [6-40] weeks vs. 21.5 [6-40], p=0.03). Fetal losses beyond 10 weeks gestation were less frequent in group A than B (2% vs 10.9%, p=0.05). Placenta mediated complications (pre-ecplampsia, abruption placenta and intrauterine growth restriction (IUGR)) were less prevalent in HCQ treated women compared to controls (2% vs. 10.9%, p=0.05).The association of HCQ with the absence of any complications in pregnancy was confirmed after multivariate analysis (OR 2.2; 95%CI [1.2-136.1]; p=0.04). <h3>Conclusions</h3> Women with aPL may benefit of treatment with HCQ during pregnancy. The addition of HCQ to conventional treatment is worthy of further assessment. <h3>Disclosure of Interest</h3> None declared
KRAS mutation in the primary or acquired resistance of Chinese NSCLC to EGFR tyrosine kinase inhibitors
Authors: H. Chen, Y. Wu, X. Zhang, Z. Chen, A. Guo, H. Cheng
Journal: Journal of Clinical Oncology (2009)

e19071 Background: Prevalence of KRAS mutation in Asian NSCLC is different to population of white ethnicity. Data about KRAS mutation after development of resistance to EGFR tyrosine kinase inhibitors (TKIs) are rare. This study was to investigate the prevalence of KRAS mutation in Chinese NSCLC after primary or acquired resistance to EGFR TKIs. Methods: 155 EGFR TKI-naive NSCLC patients and corresponding tumor specimens were collected to establish baseline of KRAS mutation. 45 specimens from six patients with primary resistance to TKIs and twenty-nine patients with acquired resistance to TKIs were analyzed. Genomic DNA was prepared after purified cancer cells were isolated by laser microdissection. Mutations in codon 12 and 13 of the KRAS gene in TKI-naive patients were analyzed by direct sequencing. Mutations in TKI-resistant patients were meanwhile detected by DxS KRAS Mutation Test Kit and direct sequencing. Results: KRAS mutation (G12X) was detected in 7.1% (11/155) of the TKI- naive patients by direct sequencing. In 6 primary resistant patients (two paired specimens and four resistant specimens) and in 29 acquired resistant patients (eight paired specimens and twenty-one resistant specimens), absence of KRAS mutation was detected in all pre- treatment and post-treatment tissues by both methods. Conclusions: KRAS mutation exists in TKI-naive NSCLC patients instead of TKI-resistant setting. KRAS mutation couldn’t thoroughly explain the primary resistance to EGFR TKIs and it might not be the crucial consideration in the mechanisms of acquired resistance. No significant financial relationships to disclose.
Typing database for noroviruses
Authors: E Duizer, A Kroneman, J Siebenga, L Verhoef, H Vennema, M Koopmans, Collective the FBVE network
Journal: Eurosurveillance (2008)

The FBVE (Food-borne Viruses in Europe) network was initiated during a research project funded by the European Commission (contract QLK1-1999-00594). The aim of the network is to establish a framework for rapid, (pre-publication) exchange of epidemiological, virological and molecular diagnostic data on outbreaks of viral gastroenteritis and acute hepatitis due to hepatitis A and E viruses for both surveillance and research purposes.
Community Care: The First Year: Newcastle: making strides
Authors: S Kingman
Journal: BMJ (1994)

In the past year those involved in implementing community care in Newcastle have been on a massive learning curve, starting to understand purchasing services, moving towards all kinds of domiciliary services. Provision of services by the independent sector is still developing, leaving the social services department to consolidate its own home care services; voluntary agencies are being contracted to supply others. A new assessment system is evolving. Joint planning is moving forward slowly.
FRI0109 Methotrexate Reduced TNF Bioactivity by Anti-Infliximab Antibody Prevention in Rheumatoid Arthritis Patients Treated with Infliximab
Authors: D. Dénarié, M. Rinaudo, T. Thomas, S. Paul, H. Marotte
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Since biologic therapy development, rheumatoid arthritis (RA) prognosis improves dramatically. Tumor necrosis factor alpha (TNF) is a proinflammatory cytokine that plays an important role in RA pathogenesis. Infliximab (IFX, Remicade®), is a human-murine chimerical monoclonal IgG antibody targeting TNF, approved for RA after inadequate response to conventional synthetic disease modifying antirheumatic drugs (csDMARDs). Clinical improvement is heterogeneous with primary or secondary therapy failure. Furthermore, no factors to predict response are available in the daily practice. Detection of antibody towards IFX (ATI) was described early in the development of this drug. The hypothesis is that ATI reduce IFX concentration associated with a lack of efficacy. <h3>Objectives</h3> To evaluate methotrexate effects on tumor necrosis factor alpha (TNF) bioactivity and antibody against infliximab (ATI) development in rheumatoid arthritis (RA) patients treated by infliximab (IFX). <h3>Methods</h3> In a longitudinal multicenter study including 39 RA patients requiring IFX therapy, clinical data and blood sample were recorded at the inclusion (W0), at the 6th week (W6), at the 6th month (W22) and at the 12th month (W54) of treatment. <h3>Results</h3> IFX trough level increased from W0 to W54 and distribution became heterogeneous at W22 at the time of first ATI detection. From W22, an inverse correlation between IFX trough level and ATI concentrations was observed (p&lt;0.05). ATI concentrations inversely correlated with EULAR response at W22 (p&lt;0.005). TNF bioactivity decreased from W0 to W6, and distribution was heterogeneous from W22. TNF bioactivity correlated with both DAS28 (p&lt;0.05) and ATI concentrations (p&lt;0.001) at W22. Methotrexate therapy was associated with absence of ATI at W22 (p&lt;0.05), and TNF bioactivity was lower than in patients with other synthetic disease modifying antirheumatic drugs (p&lt;0.005). <h3>Conclusions</h3> This suggests that methotrexate plays a key role on TNF bioactivity and against ATI development <h3>Disclosure of Interest</h3> None declared
Endoscopic ultrasound-guided pelvic abscess drainage using a dedicated, wide, flared-end, fully covered self-expandable metal stent
Authors: Hiroshi Kawakami, Masaki Kuwatani, Shuhei Kawahata, Yoshimasa Kubota, Kimitoshi Kubo, Kazumichi Kawakubo, Naoya Sakamoto
Journal: Endoscopy (2015)

Endoscopic ultrasound (EUS) can be used to guide drainage of pelvic abscesses. Here, we present a case of successful pelvic abscess drainage using a dedicated, wide, flared-end, fully covered self-expandable metal stent (FCSEMS).
Zebrafish Xenotransplantation and Focused Chemical Genomics: A Preclinical Therapeutic Model For T-Cell Acute Lymphoblastic Leukemia
Authors: Victoria L Bentley, Chansey J Veinotte, Dale Corkery, Marissa A Leblanc, Karen Bedard, Andrew P Weng, Graham Dellaire, Jason N Berman
Journal: Blood (2013)
Psychiatry and the fiscal third party
Authors: P Chodoff
Journal: American Journal of Psychiatry (1978)

Third-party payment has profound effects on such areas of psychiatry as confidentiality; diagnosis; the therapeutic relationship; psychiatry's identification with the rest of medicine and the role of nonphysician mental health professionals; psychiatric education; and the availability, type, location, and quality control of treatment. As third-party payment becomes increasingly frequent, psychiatrists will have to come to terms with its good and bad effects in hospitals and community mental health centers as well as in private practice.
The Human Genome Project
Authors: Emil Aschheim
Journal: JAMA (1992)

To the Editor.  —Green and Waterston 1 justly emphasize the biological and medical benefits of the Human Genome Project. However, the significance of this project goes well beyond the cure or prevention of identifiable medical conditions.  This epochal project will locate and identify the genes that are responsible for all human characteristics, including those that are essential to the development of memory, intelligence, creativity, and awareness. Human awareness and cognition characterize our race prominently and uniquely; aren't they as likely to be gene dependent as is the number of cervical vertebrae or the color of the eyes?  The knowledge gained will mark the beginning of an era of unprecedented change, since national and individual interest will make human-directed evolution inevitable. The process is likely to go beyond the traditional goals of eugenics. Human variants genetically engineered to fit environments or tasks may not be unthinkable.  Who will share in the knowledge
Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy
Authors: James Mattina, Nathalie MacKinnon, Valerie C. Henderson, Dean Fergusson, Jonathan Kimmelman
Journal: Cancer Research (2016)

The validity of preclinical studies of candidate therapeutic agents has been questioned given their limited ability to predict their fate in clinical development, including due to design flaws and reporting bias. In this study, we examined this issue in depth by conducting a meta-analysis of animal studies investigating the efficacy of the clinically approved kinase inhibitor, sorafenib. MEDLINE, Embase, and BIOSIS databases were searched for all animal experiments testing tumor volume response to sorafenib monotherapy in any cancer published until April 20, 2012. We estimated effect sizes from experiments assessing changes in tumor volume and conducted subgroup analyses based on prespecified experimental design elements associated with internal, construct, and external validity. The meta-analysis included 97 experiments involving 1,761 animals. We excluded 94 experiments due to inadequate reporting of data. Design elements aimed at reducing internal validity threats were implemented only sporadically, with 66% reporting animal attrition and none reporting blinded outcome assessment or concealed allocation. Anticancer activity against various malignancies was typically tested in only a small number of model systems. Effect sizes were significantly smaller when sorafenib was tested against either a different active agent or combination arm. Trim and fill suggested a 37% overestimation of effect sizes across all malignancies due to publication bias. We detected a moderate dose-response in one clinically approved indication, hepatocellular carcinoma, but not in another approved malignancy, renal cell carcinoma, or when data were pooled across all malignancies tested. In support of other reports, we found that few preclinical cancer studies addressed important internal, construct, and external validity threats, limiting their clinical generalizability. Our findings reinforce the need to improve guidelines for the design and reporting of preclinical cancer studies. Cancer Res; 76(16); 4627-36. ©2016 AACR.
Identification of Some Polynuclear Aromatic Hydrocarbons in Cigarette-Smoke Condensate<xref ref-type="fn" rid="FN1">2</xref>,<xref ref-type="fn" rid="FN2">3</xref>
Authors: Benjamin L. Van Duuren
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article Identification of Some Polynuclear Aromatic Hydrocarbons in Cigarette-Smoke Condensate, Get access Benjamin L. Van Duuren Benjamin L. Van Duuren Institute of Industrial Medicine, New York University-Bellevue Medical Center, New York, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 21, Issue 1, July 1958, Pages 1–16, https://doi.org/10.1093/jnci/21.1.1 Published: 01 July 1958 Article history Received: 07 November 1957 Published: 01 July 1958
Case 23-1964
Authors: Edwin P. Maynard, Benjamin Castleman
Journal: New England Journal of Medicine (1964)

Presentation of CaseA thirty-seven-year-old truck driver was admitted to the hospital because of jaundice.Eight months previously he began to experience episodes of belching and pain in the right upper quadrant of the abdomen after the ingestion of a fatty meal. Four months before entry an x-ray film of the gallbladder revealed cholelithiasis. One week later he entered another hospital because of the development of severe pain in the epigastrium, the right upper quadrant of the abdomen and the right side of the chest, accompanied by nausea and vomiting. Electrocardiograms disclosed the appearance and evolution of a myocardial infarction . . .
FRI0202 The Relationship Between Disease Activity, Functional Index, Sleep Quality, Anxiety, Depression, Fatigue and Quality of Life in Patients with Ankylosing Spondylitis
Authors: A. Ates, F. Dortbas, Y. Karaaslan
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Sleep problems, psychological factors may be important in the assessment and management of ankylosing spondylitis (AS). <h3>Objectives</h3> To compare sleep quality of AS patients with that of healthy controls (HC) and its association with disease spesific variables, emotional status (anxiety and depression), fatigue level and quality of life. <h3>Methods</h3> A total of 60 patients (40 male and 20 female)), who fulfilled the modified New York criteria and 30 age and sex-matched healthy controls were enrolled. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Functional Index (BASFI), The Pittsburg Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale, Fatigue Severity Scale and AS-spesific quality of life (ASQoL) were assessed. The cutoff scores are estimated as 10 and 7 for anxiety and depression scale, respectively. A score of 4 or higher and a score of higher than 5 indicates severe fatigue and poor sleep quality, respectively. <h3>Results</h3> AS patients had statistically significant poorer sleep quality, higher depression and fatigue scores than those compared to healthy controls (Table1). The AS patients with high disease activity score (BASDAI ≥4) had statistically significant poorer sleep quality (4 and 8, p&lt;0,001), higher depression (5 and 8, p=0,02) and fatigue (4,1 and 5,1; p&lt;0,001) scores, worse ASQoL (4 and 11, p&lt;0,001) than those compared to the patients with low disease activity. In AS patients, there were significant correlations between disease variables (BASDAI and BASFI), PSQI, Hospital Anxiety and Depression Scale, Fatigue Severity Scale and ASQoL (Table 2). AS patients using only nonsteroid antiinflammatory drugs (n=11) had poorer PSQI score than that compared to AS patients under anti-TNF (n=15) (9 and 4; p&lt;0,05)and DMARD therapies (n=34) (9 and 5,5; p=0,019) and HC (9 and 3; p&lt;0,001), respectively. <h3>Conclusions</h3> Sleep problems, depression, fatigue and worse QoL are prevalent in patients with AS. Our results showed that the psychological status and quality of life had close interaction with disease activity and functional index. Consequently, when planning the treatment strategies of AS patients, all of these factors should be taken into consideration. <h3>Disclosure of Interest</h3> None declared